Lawton Alison Frances 4

What Happened

• Alison Lawton, a director of Dianthus Therapeutics, was granted a stock option award covering 6,090 underlying shares, reported as an acquisition at $0.00 on 2026-05-21. This was a derivative (stock option) award — no shares were sold or bought for cash in this transaction.

Key Details

• Transaction date: 2026-05-21; SEC filing date: 2026-05-22 (timely).
• Grant: 6,090 shares (derivative stock option); reported acquisition price: $0.00.
• Shares owned after transaction: not disclosed in this Form 4.
• Footnote: The options vest in full on the earlier of (i) the first anniversary of the grant or (ii) the issuer’s 2027 Annual Meeting of Stockholders, subject to continued service.
• Filing timeliness: filed the day after the report date (no late filing noted).

Context

• This is a typical director equity grant used as compensation and does not represent an open-market purchase or sale. The $0.00 figure reflects the reporting convention for option grants on Form 4; the award must vest (per the footnote) before the underlying shares are received or exercisable under the stated conditions.